SAGA Diagnostics
AcquiredRedefining the early detection of molecular residual disease (MRD)
- Website
- sagadiagnostics.com
- Total Funding
- $16.6M
- Last Round
- $4.1M Venture RoundJun 2021
- Rounds
- 2
- Acquisition Date
- Apr 2026
About
SAGA Diagnostics's mission is to intercept cancer at the earliest stages when it's most treatable. The company is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Pathlight, the company's flagship product, is an ultra-sensitive, blood-based, multi-cancer MRD test that is now available for commercial use in the U.S. Its headquarters and CLIA-certified laboratory are located in Research Triangle Park, North Carolina, with additional facilities in Lund, Sweden.
Summary
SAGA Diagnostics is a Biotech company. It has raised $16.6M in total across 2 rounds, most recently a $4.1M Venture Round round in Jun 2021. Investors include Sciety.
Funding History
Apr 2026
Sign up to see all 3 rounds
Venture Round through Acquisition — per-round amounts, valuations, and who invested in each round.
Investors
Similar Companies
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Biotechnology company developing multi-cancer early detection blood tests using high-intensity ge...
Ultima Genomics develops high-throughput DNA sequencing platforms that use open-wafer technology ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...
China's leading blood products manufacturer
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/saga-diagnostics"><img src="https://indexed.vc/api/badge/company/saga-diagnostics" alt="SAGA Diagnostics on Indexed.vc" width="260" height="76" /></a>